Group 1 - The core viewpoint of the news is that Hunan Maijizhi Biotechnology Co., Ltd. (referred to as Maijizhi) submitted its Hong Kong IPO prospectus on July 14, 2025, which will expire on January 14, 2026, with CICC as its sole sponsor [1] - Maijizhi is a biopharmaceutical company in the clinical registration stage, focusing on the discovery, development, and commercialization of innovative biopharmaceuticals to address unmet medical needs related to allergic and autoimmune diseases, as well as other inflammatory and immune diseases [2] - Since its establishment in 2016, the company has developed a strong pipeline consisting of eight innovative candidate products, including core product MG-K10, key products MG-014 and MG-013, along with five other candidate products, all of which are next-generation long-acting antibodies discovered and developed through the company's proprietary technology platform [2]
新股消息 | 麦济生物港股IPO招股书失效
智通财经网·2026-01-14 02:47